Much anticipated Alzheimer Disease prevention trial finds no clinical benefit from drug targeting amyloid; highlights need to consider other approaches.

Much Anticipated Alzheimer Disease Prevention Trial Finds No Clinical Benefit From Drug Targeting Amyloid; Highlights Need to Consider Other Approaches – JAMA (free for a limited period)

Commentary on Twitter

The hypothesis that amyloid deposits in the brain cause Alzheimer disease has gotten many hits over the years, as one antiamyloid treatment after another failed to show a clinical benefit. Time to move on? @RitaRubin writes about the debate. https://t.co/913A0WWcR7

— JAMA (@JAMA_current) August 17, 2022